-+ 0.00%
-+ 0.00%
-+ 0.00%

*Johnson & Johnson To Acquire Ollin Biosciences And Late-stage Bispecific Antibody With Best-in-class Potential In Ophthalmology >JNJ

Dow Jones·11/16/2026 13:00:00

Please log in to view news